Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Cirrhosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 192 articles:
HTML format
Text format



Single Articles


    January 2019
  1. REZAEI N, Asadi-Lari M, Sheidaei A, Khademi S, et al
    Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
    PLoS One. 2019;14:e0198449.
    PubMed     Text format     Abstract available


  2. SCHWARZKOPF KM, Queck A, Thomas D, Angioni C, et al
    Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation.
    PLoS One. 2019;14:e0211537.
    PubMed     Text format     Abstract available


  3. TAKADA H, Kurosaki M, Nakanishi H, Takahashi Y, et al
    Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    PLoS One. 2019;14:e0211122.
    PubMed     Text format     Abstract available


  4. MUKTHINUTHALAPATI VVPK, Akinyeye S, Fricker ZP, Syed M, et al
    Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals.
    PLoS One. 2019;14:e0211811.
    PubMed     Text format     Abstract available


  5. HUANG CH, Wu LS, Jeng WJ, Cheng YF, et al
    In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.
    PLoS One. 2019;14:e0212770.
    PubMed     Text format     Abstract available


  6. DU Z, Dong J, Bi J, Bai R, et al
    Correction: Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2019;14:e0215183.
    PubMed     Text format     Abstract available


  7. HUNG TH, Tseng CW, Tsai CC, Lee HF, et al
    Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia.
    PLoS One. 2019;14:e0216041.
    PubMed     Text format     Abstract available


  8. HUNG TH, Tsai CC, Lee HF
    Statin use in cirrhotic patients with infectious diseases: A population-based study.
    PLoS One. 2019;14:e0215839.
    PubMed     Text format     Abstract available


    January 2018
  9. LIU TL, Barritt AS Th, Weinberger M, Paul JE, et al
    Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis.
    PLoS One. 2018;13:e0190756.
    PubMed     Text format     Abstract available


  10. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Text format     Abstract available


  11. BUCSICS T, Schoder M, Diermayr M, Feldner-Busztin M, et al
    Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.
    PLoS One. 2018;13:e0189414.
    PubMed     Text format     Abstract available


  12. SARACINO A, Cozzi-Lepri A, Shanyinde M, Ceccherini Silberstein F, et al
    HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.
    PLoS One. 2018;13:e0190302.
    PubMed     Text format     Abstract available


  13. RAUBER P, Lammert F, Grotemeyer K, Appenrodt B, et al
    Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study.
    PLoS One. 2018;13:e0192271.
    PubMed     Text format     Abstract available


  14. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Text format     Abstract available


  15. MULABECIROVIC A, Mjelle AB, Gilja OH, Vesterhus M, et al
    Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems.
    PLoS One. 2018;13:e0189671.
    PubMed     Text format     Abstract available


  16. YAMADA K, Mizukoshi E, Seike T, Horii R, et al
    Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0191026.
    PubMed     Text format     Abstract available


  17. LIAO CY, Chung CH, Chu P, Wei KY, et al
    Increased risk of osteoporosis in patients with primary biliary cirrhosis.
    PLoS One. 2018;13:e0194418.
    PubMed     Text format     Abstract available


  18. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Text format     Abstract available


  19. LE CT, Nguyen G, Park SY, Choi DH, et al
    LY2405319, an analog of fibroblast growth factor 21 ameliorates alpha-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice.
    PLoS One. 2018;13:e0192146.
    PubMed     Text format     Abstract available


  20. DU Z, Dong J, Bi J, Bai R, et al
    Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2018;13:e0195336.
    PubMed     Text format     Abstract available


  21. JANSEN C, Al-Kassou B, Lehmann J, Pohlmann A, et al
    Severe abnormal Heart Rate Turbulence Onset is associated with deterioration of liver cirrhosis.
    PLoS One. 2018;13:e0195631.
    PubMed     Text format     Abstract available


  22. HEMMINGER J, Arole V, Ayoub I, Brodsky SV, et al
    Acute glomerulonephritis with large confluent IgA-dominant deposits associated with liver cirrhosis.
    PLoS One. 2018;13:e0193274.
    PubMed     Text format     Abstract available


  23. YETTI H, Naito H, Yuan Y, Jia X, et al
    Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet.
    PLoS One. 2018;13:e0192863.
    PubMed     Text format     Abstract available


  24. YUAN LT, Chuah SK, Yang SC, Liang CM, et al
    Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis.
    PLoS One. 2018;13:e0197127.
    PubMed     Text format     Abstract available


  25. KROHN S, Zeller K, Bohm S, Chatzinotas A, et al
    Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis.
    PLoS One. 2018;13:e0197319.
    PubMed     Text format     Abstract available


  26. NGUYEN HH, Shaheen AA, Baeza N, Lytvyak E, et al
    Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).
    PLoS One. 2018;13:e0193960.
    PubMed     Text format     Abstract available


  27. MAYR U, Karsten E, Lahmer T, Rasch S, et al
    Impact of large volume paracentesis on respiratory parameters including transpulmonary pressure and on transpulmonary thermodilution derived hemodynamics: A prospective study.
    PLoS One. 2018;13:e0193654.
    PubMed     Text format     Abstract available


  28. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Text format     Abstract available


  29. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Text format     Abstract available


  30. SHAHEEN AA, Kaplan GG, Almishri W, Vallerand I, et al
    The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    PLoS One. 2018;13:e0194839.
    PubMed     Text format     Abstract available


  31. BIAN S, Chen H, Wang L, Fei Y, et al
    Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study.
    PLoS One. 2018;13:e0194397.
    PubMed     Text format     Abstract available


  32. KELLER S, Aigner A, Zenouzi R, Kim AC, et al
    Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
    PLoS One. 2018;13:e0193929.
    PubMed     Text format     Abstract available


  33. SATSANGI S, Duseja A, Sachdeva M, Tomer S, et al
    Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure.
    PLoS One. 2018;13:e0200644.
    PubMed     Text format     Abstract available


  34. FINKELMEIER F, Canli O, Peiffer KH, Walter D, et al
    Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
    PLoS One. 2018;13:e0200855.
    PubMed     Text format     Abstract available


  35. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Text format     Abstract available


  36. FRIEDMAN A, Siewe N
    Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PLoS One. 2018;13:e0195037.
    PubMed     Text format     Abstract available


  37. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    PubMed     Text format     Abstract available


  38. ONICIU DC, Hashiguchi T, Shibazaki Y, Bisgaier CL, et al
    Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH.
    PLoS One. 2018;13:e0194568.
    PubMed     Text format     Abstract available


  39. AXLEY P, Mudumbi S, Sarker S, Kuo YF, et al
    Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications.
    PLoS One. 2018;13:e0197117.
    PubMed     Text format     Abstract available


  40. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Text format     Abstract available


  41. EYRAUD D, Suner L, Dupont A, Bachelot-Loza C, et al
    Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month.
    PLoS One. 2018;13:e0200364.
    PubMed     Text format     Abstract available


  42. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Text format     Abstract available


  43. REITER R, Wetzel M, Hamesch K, Strnad P, et al
    Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE).
    PLoS One. 2018;13:e0196486.
    PubMed     Text format     Abstract available


  44. PEISELER M, Reiners D, Pinnschmidt HO, Sebode M, et al
    Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.
    PLoS One. 2018;13:e0202686.
    PubMed     Text format     Abstract available


  45. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Text format     Abstract available


  46. LAPOINTE-SHAW L, Georgie F, Carlone D, Cerocchi O, et al
    Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.
    PLoS One. 2018;13:e0201120.
    PubMed     Text format     Abstract available


  47. ALKHOURI N, Johnson C, Adams L, Kitajima S, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    PLoS One. 2018;13:e0202226.
    PubMed     Text format     Abstract available


  48. KIMER N, Gudmann NS, Pedersen JS, Moller S, et al
    No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
    PLoS One. 2018;13:e0203200.
    PubMed     Text format     Abstract available


  49. IOANNOU GN, Green P, Lowy E, Mun EJ, et al
    Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.
    PLoS One. 2018;13:e0204412.
    PubMed     Text format     Abstract available


  50. ALKHOURI N, Johnson C, Adams L, Kitajima S, et al
    Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    PLoS One. 2018;13:e0205541.
    PubMed     Text format     Abstract available


  51. KUBESCH A, Quenstedt L, Saleh M, Ruschenbaum S, et al
    Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study.
    PLoS One. 2018;13:e0207162.
    PubMed     Text format     Abstract available


  52. KHAN B, Duncan I, Saad M, Schaefer D, et al
    Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.
    PLoS One. 2018;13:e0206356.
    PubMed     Text format     Abstract available


  53. HSIEH YC, Lee KC, Wang YW, Yang YY, et al
    Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score.
    PLoS One. 2018;13:e0208903.
    PubMed     Text format     Abstract available


  54. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Text format     Abstract available


  55. WANG HW, Shi HN, Cheng J, Xie F, et al
    Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: A pilot study.
    PLoS One. 2018;13:e0197550.
    PubMed     Text format     Abstract available


  56. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Text format     Abstract available


  57. ABE K, Takahashi A, Fujita M, Imaizumi H, et al
    Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease.
    PLoS One. 2018;13:e0198757.
    PubMed     Text format     Abstract available


  58. CHANG PE, Goh GBB, Leow WQ, Shen L, et al
    Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0199166.
    PubMed     Text format     Abstract available


  59. OBMANN VC, Mertineit N, Berzigotti A, Marx C, et al
    CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scans.
    PLoS One. 2018;13:e0199611.
    PubMed     Text format     Abstract available


  60. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Text format     Abstract available


  61. KIM SE, Park JW, Kim MJ, Jang B, et al
    Accumulation of citrullinated glial fibrillary acidic protein in a mouse model of bile duct ligation-induced hepatic fibrosis.
    PLoS One. 2018;13:e0201744.
    PubMed     Text format     Abstract available


  62. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Text format     Abstract available


  63. PELEG N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, et al
    Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease.
    PLoS One. 2018;13:e0202393.
    PubMed     Text format     Abstract available


  64. ALISI A, Pampanini V, De Stefanis C, Panera N, et al
    Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD.
    PLoS One. 2018;13:e0201566.
    PubMed     Text format     Abstract available


  65. KRUK B, Liebe R, Milkiewicz M, Wunsch E, et al
    PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
    PLoS One. 2018;13:e0202942.
    PubMed     Text format     Abstract available


  66. HARRISON SA, Dennis A, Fiore MM, Kelly MD, et al
    Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.
    PLoS One. 2018;13:e0203054.
    PubMed     Text format     Abstract available


  67. FRANSEN PETTERSSON N, Deronic A, Nilsson J, Hannibal TD, et al
    The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis.
    PLoS One. 2018;13:e0203228.
    PubMed     Text format     Abstract available


  68. XING YF, Zhou DQ, He JS, Wei CS, et al
    Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    PLoS One. 2018;13:e0203220.
    PubMed     Text format     Abstract available


  69. DILLARD KJ, Hytonen MK, Fischer D, Tanhuanpaa K, et al
    A splice site variant in INPP5E causes diffuse cystic renal dysplasia and hepatic fibrosis in dogs.
    PLoS One. 2018;13:e0204073.
    PubMed     Text format     Abstract available


  70. ROMUALDO GR, Prata GB, da Silva TC, Fernandes AAH, et al
    Fibrosis-associated hepatocarcinogenesis revisited: Establishing standard medium-term chemically-induced male and female models.
    PLoS One. 2018;13:e0203879.
    PubMed     Text format     Abstract available


  71. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    PubMed     Text format     Abstract available


  72. MCCLURE MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, et al
    Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    PLoS One. 2018;13:e0204974.
    PubMed     Text format     Abstract available


  73. POLINENI D, Piccorelli AV, Hannah WB, Dalrymple SN, et al
    Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.
    PLoS One. 2018;13:e0205257.
    PubMed     Text format     Abstract available


  74. ALMEER RS, El-Khadragy MF, Abdelhabib S, Abdel Moneim AE, et al
    Ziziphus spina-christi leaf extract ameliorates schistosomiasis liver granuloma, fibrosis, and oxidative stress through downregulation of fibrinogenic signaling in mice.
    PLoS One. 2018;13:e0204923.
    PubMed     Text format     Abstract available


  75. LEE SH, Park M, Park KM, Gwag HB, et al
    Corrected QT interval on the electrocardiogram after liver transplantation: Surrogate marker of poor clinical outcomes?
    PLoS One. 2018;13:e0206463.
    PubMed     Text format     Abstract available


  76. FAROUK S, Sabet S, Abu Zahra FA, El-Ghor AA, et al
    Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis.
    PLoS One. 2018;13:e0206130.
    PubMed     Text format     Abstract available


  77. LIU C, Wang L, Xie H, Zhang L, et al
    The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection.
    PLoS One. 2018;13:e0206060.
    PubMed     Text format     Abstract available


  78. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    PubMed     Text format     Abstract available


  79. DAHER S, Lev Cohen N, Massarwa M, Mahamid M, et al
    Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0207479.
    PubMed     Text format     Abstract available


  80. CHENG PN, Chiu HC, Chiu YC, Chen SC, et al
    Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
    PLoS One. 2018;13:e0206947.
    PubMed     Text format     Abstract available


  81. BILLA O, Chalouni M, Salmon D, Poizot-Martin I, et al
    Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.
    PLoS One. 2018;13:e0208657.
    PubMed     Text format     Abstract available


  82. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    PLoS One. 2018;13:e0209374.
    PubMed     Text format     Abstract available


  83. PAPIC N, Zidovec Lepej S, Gorenec L, Grgic I, et al
    The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
    PLoS One. 2018;13:e0209481.
    PubMed     Text format     Abstract available


    January 2017
  84. YANG SC, Hsu CN, Liang CM, Tai WC, et al
    Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study.
    PLoS One. 2017;12:e0168918.
    PubMed     Text format     Abstract available


  85. DEGRE D, Serste T, Lasser L, Delwaide J, et al
    Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PLoS One. 2017;12:e0170933.
    PubMed     Text format     Abstract available


  86. GIMENEZ-GARZO C, Garces JJ, Urios A, Mangas-Losada A, et al
    The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.
    PLoS One. 2017;12:e0171211.
    PubMed     Text format     Abstract available


  87. TRAYKOVA D, Schneider B, Chojkier M, Buck M, et al
    Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients.
    PLoS One. 2017;12:e0169310.
    PubMed     Text format     Abstract available


  88. HOLLENBACH M, Thonig A, Pohl S, Ripoll C, et al
    Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis.
    PLoS One. 2017;12:e0171260.
    PubMed     Text format     Abstract available


  89. BECKER S, Kinny-Koster B, Bartels M, Scholz M, et al
    Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis.
    PLoS One. 2017;12:e0174424.
    PubMed     Text format     Abstract available


  90. WANG YC, Chou CT, Lin CP, Chen YL, et al
    The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    PLoS One. 2017;12:e0174594.
    PubMed     Text format     Abstract available


  91. GAO B, Zhang X, Huang Y, Yang Z, et al
    Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis.
    PLoS One. 2017;12:e0174142.
    PubMed     Text format     Abstract available


  92. YE Q, Yin W, Zhang L, Xiao H, et al
    The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis.
    PLoS One. 2017;12:e0175165.
    PubMed     Text format     Abstract available


  93. IBUSUKI R, Uto H, Oda K, Ohshige A, et al
    Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis.
    PLoS One. 2017;12:e0174913.
    PubMed     Text format     Abstract available


  94. KREMERS RMW, Kleinegris MC, Ninivaggi M, de Laat B, et al
    Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.
    PLoS One. 2017;12:e0177020.
    PubMed     Text format     Abstract available


  95. YOON K, Jeong WK, Kim Y, Kim MY, et al
    2-dimensional shear wave elastography: Interobserver agreement and factors related to interobserver discrepancy.
    PLoS One. 2017;12:e0175747.
    PubMed     Text format     Abstract available


  96. MCPHERSON S, Wilkinson N, Tiniakos D, Wilkinson J, et al
    A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    PLoS One. 2017;12:e0175717.
    PubMed     Text format     Abstract available


  97. LI Z, Lin B, Lin G, Wu Y, et al
    Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.
    PLoS One. 2017;12:e0178580.
    PubMed     Text format     Abstract available


  98. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Text format     Abstract available


  99. HAN EC, Ryoo SB, Park JW, Yi JW, et al
    Oncologic and surgical outcomes in colorectal cancer patients with liver cirrhosis: A propensity-matched study.
    PLoS One. 2017;12:e0178920.
    PubMed     Text format     Abstract available


  100. CHANG CC, Lee WS, Hsieh HG, Chuang CL, et al
    Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
    PLoS One. 2017;12:e0179809.
    PubMed     Text format     Abstract available


  101. HUNG TH, Liang CM, Hsu CN, Tai WC, et al
    Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
    PLoS One. 2017;12:e0181858.
    PubMed     Text format     Abstract available


  102. WU CK, Liang CM, Hsu CN, Hung TH, et al
    The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation.
    PLoS One. 2017;12:e0169884.
    PubMed     Text format     Abstract available


  103. ZHAO J, Zhai F, Cheng J, He Q, et al
    Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography.
    PLoS One. 2017;12:e0170073.
    PubMed     Text format     Abstract available


  104. DONAIRES FS, Scatena NF, Alves-Paiva RM, Podlevsky JD, et al
    Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
    PLoS One. 2017;12:e0183287.
    PubMed     Text format     Abstract available


  105. LIU X, He L, Han J, Wang L, et al
    Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer.
    PLoS One. 2017;12:e0170605.
    PubMed     Text format     Abstract available


  106. ZHANG BB, Yan C, Fang F, Du Y, et al
    Increased hepatic Th2 and Treg subsets are associated with biliary fibrosis in different strains of mice caused by Clonorchis sinensis.
    PLoS One. 2017;12:e0171005.
    PubMed     Text format     Abstract available


  107. SALDANA RS, Schrem H, Barthold M, Kaltenborn A, et al
    Prognostic Abilities and Quality Assessment of Models for the Prediction of 90-Day Mortality in Liver Transplant Waiting List Patients.
    PLoS One. 2017;12:e0170499.
    PubMed     Text format     Abstract available


  108. WANG L, Feng Y, Ma X, Wang G, et al
    Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.
    PLoS One. 2017;12:e0182969.
    PubMed     Text format     Abstract available


  109. LE MH, Devaki P, Ha NB, Jun DW, et al
    Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    PLoS One. 2017;12:e0173499.
    PubMed     Text format     Abstract available


  110. GARDINALI NR, Guimaraes JR, Melgaco JG, Kevorkian YB, et al
    Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.
    PLoS One. 2017;12:e0174070.
    PubMed     Text format     Abstract available


  111. STAHMEYER JT, Rossol S, Liersch S, Guerra I, et al
    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PLoS One. 2017;12:e0169401.
    PubMed     Text format     Abstract available


  112. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Text format     Abstract available


  113. KOMIYAMA Y, Kurosaki M, Nakanishi H, Takahashi Y, et al
    Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    PLoS One. 2017;12:e0174649.
    PubMed     Text format     Abstract available


  114. DIJKSTRA H, Wolff D, van Melle JP, Bartelds B, et al
    Diminished liver microperfusion in Fontan patients: A biexponential DWI study.
    PLoS One. 2017;12:e0173149.
    PubMed     Text format     Abstract available


  115. LEE SM, Lee JM, Kang HJ, Yang HK, et al
    Liver fibrosis staging with a new 2D-shear wave elastography using comb-push technique: Applicability, reproducibility, and diagnostic performance.
    PLoS One. 2017;12:e0177264.
    PubMed     Text format     Abstract available


  116. ROKUSZ A, Veres D, Szucs A, Bugyik E, et al
    Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.
    PLoS One. 2017;12:e0176518.
    PubMed     Text format     Abstract available


  117. YANG KL, Chang WT, Hong MY, Hung KC, et al
    Prevention of TGF-beta-induced early liver fibrosis by a maleic acid derivative anti-oxidant through suppression of ROS, inflammation and hepatic stellate cells activation.
    PLoS One. 2017;12:e0174008.
    PubMed     Text format     Abstract available


  118. KRAWCZYK M, Zimmermann S, Hess G, Holz R, et al
    Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease.
    PLoS One. 2017;12:e0173506.
    PubMed     Text format     Abstract available


  119. SONG YN, Dong S, Wei B, Liu P, et al
    Metabolomic mechanisms of gypenoside against liver fibrosis in rats: An integrative analysis of proteomics and metabolomics data.
    PLoS One. 2017;12:e0173598.
    PubMed     Text format     Abstract available


  120. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2017;12:e0172159.
    PubMed     Text format     Abstract available


  121. JOLY P, Vignaud H, Di Martino J, Ruiz M, et al
    ERAD defects and the HFE-H63D variant are associated with increased risk of liver damages in Alpha 1-Antitrypsin Deficiency.
    PLoS One. 2017;12:e0179369.
    PubMed     Text format     Abstract available


  122. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Text format     Abstract available


  123. LAI LL, Chan WK, Sthaneshwar P, Nik Mustapha NR, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0174982.
    PubMed     Text format     Abstract available


  124. DOLD L, Luda C, Schwarze-Zander C, Boesecke C, et al
    Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).
    PLoS One. 2017;12:e0178685.
    PubMed     Text format     Abstract available


  125. KRAUSKOPF J, de Kok TM, Schomaker SJ, Gosink M, et al
    Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.
    PLoS One. 2017;12:e0177928.
    PubMed     Text format     Abstract available


  126. LIN WC, Lin HH, Hung CY, Shih SC, et al
    Clinical endoscopic management and outcome of post-endoscopic sphincterotomy bleeding.
    PLoS One. 2017;12:e0177449.
    PubMed     Text format     Abstract available


  127. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Text format     Abstract available


  128. WONG MW, Chen MJ, Chen HL, Kuo YC, et al
    Application of chronic liver failure-sequential organ failure assessment score for the predication of mortality after esophageal variceal hemorrhage post endoscopic ligation.
    PLoS One. 2017;12:e0182529.
    PubMed     Text format     Abstract available


  129. KIM G, Kim KJ, Rhee Y, Lim SK, et al
    Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0182202.
    PubMed     Text format     Abstract available


  130. CAI G, Chen B, Li Z, Wei W, et al
    The different expressed serum proteins in rhCygb treated rat model of liver fibrosis by the optimized two-dimensional gel electrophoresis.
    PLoS One. 2017;12:e0177968.
    PubMed     Text format     Abstract available


  131. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Text format     Abstract available


  132. CHANG JY, Kim SE, Kim TH, Woo SY, et al
    Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients.
    PLoS One. 2017;12:e0186120.
    PubMed     Text format     Abstract available


  133. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Text format     Abstract available


  134. PRESTIGIACOMO V, Weston A, Messner S, Lampart F, et al
    Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis.
    PLoS One. 2017;12:e0179995.
    PubMed     Text format     Abstract available


  135. LE CORVEC M, Jezequel C, Monbet V, Fatih N, et al
    Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis.
    PLoS One. 2017;12:e0185997.
    PubMed     Text format     Abstract available


  136. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Text format     Abstract available


  137. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Text format     Abstract available


  138. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Text format     Abstract available


  139. LI J, Ghazwani M, Liu K, Huang Y, et al
    Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism.
    PLoS One. 2017;12:e0182679.
    PubMed     Text format     Abstract available


  140. KIM G, Kang SH, Kim MY, Baik SK, et al
    Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186990.
    PubMed     Text format     Abstract available


  141. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Text format     Abstract available


  142. GARCIA-GARCIA R, Cruz-Gomez AJ, Mangas-Losada A, Urios A, et al
    Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy.
    PLoS One. 2017;12:e0186463.
    PubMed     Text format     Abstract available


  143. BHAT M, Tazari M, Sebastiani G
    Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis.
    PLoS One. 2017;12:e0185192.
    PubMed     Text format     Abstract available


  144. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Text format     Abstract available


  145. FRIEDRICH-RUST M, Schoelzel F, Maier S, Seeger F, et al
    Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study.
    PLoS One. 2017;12:e0186720.
    PubMed     Text format     Abstract available


  146. KARTOUN U, Corey KE, Simon TG, Zheng H, et al
    The MELD-Plus: A generalizable prediction risk score in cirrhosis.
    PLoS One. 2017;12:e0186301.
    PubMed     Text format     Abstract available


  147. HUBER W, Gruber A, Eckmann M, Elkmann F, et al
    Comparison of pulmonary vascular permeability index PVPI and global ejection fraction GEF derived from jugular and femoral indicator injection using the PiCCO-2 device: A prospective observational study.
    PLoS One. 2017;12:e0178372.
    PubMed     Text format     Abstract available


  148. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Text format     Abstract available


  149. YE Y, Li Z, Feng Q, Chen Z, et al
    Downregulation of microRNA-145 may contribute to liver fibrosis in biliary atresia by targeting ADD3.
    PLoS One. 2017;12:e0180896.
    PubMed     Text format     Abstract available


  150. YOKOTA T, Omachi K, Suico MA, Kojima H, et al
    Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
    PLoS One. 2017;12:e0183959.
    PubMed     Text format     Abstract available


  151. ROGAL SS, Udawatta V, Akpan I, Moghe A, et al
    Risk factors for hospitalizations among patients with cirrhosis: A prospective cohort study.
    PLoS One. 2017;12:e0187176.
    PubMed     Text format     Abstract available


  152. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Text format     Abstract available


  153. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Text format     Abstract available


  154. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Text format     Abstract available


  155. XIAO H, Shi M, Xie Y, Chi X, et al
    Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186660.
    PubMed     Text format     Abstract available


  156. YINDOM LM, Mendy M, Bodimeade C, Chambion C, et al
    KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
    PLoS One. 2017;12:e0188307.
    PubMed     Text format     Abstract available


  157. SANDAHL TD, Stoy SH, Laursen TL, Rodgaard-Hansen S, et al
    The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.
    PLoS One. 2017;12:e0189345.
    PubMed     Text format     Abstract available


  158. LEE MS, Bae JM, Joo SK, Woo H, et al
    Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease.
    PLoS One. 2017;12:e0188321.
    PubMed     Text format     Abstract available


  159. PINHEIRO D, Leiros L, Dau JBT, Stumbo AC, et al
    Cytokines, hepatic cell profiling and cell interactions during bone marrow cell therapy for liver fibrosis in cholestatic mice.
    PLoS One. 2017;12:e0187970.
    PubMed     Text format     Abstract available


  160. ALAZAWI W, Bernabe E, Tai D, Janicki T, et al
    Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0185902.
    PubMed     Text format     Abstract available


  161. FEIG JL, Mediero A, Corciulo C, Liu H, et al
    The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.
    PLoS One. 2017;12:e0188135.
    PubMed     Text format     Abstract available


  162. ZHENG XY, Zhao X, Yang YF, Jiang HJ, et al
    Antioxidant, antiapoptotic and amino acid balance regulating activities of 1,7-dihydroxy-3,4,8-trimethoxyxanthone against dimethylnitrosamine-induced liver fibrosis.
    PLoS One. 2017;12:e0189344.
    PubMed     Text format     Abstract available


    January 2016
  163. SANSOE G, Aragno M, Mastrocola R, Mengozzi G, et al
    Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data.
    PLoS One. 2016;11:e0162644.
    PubMed     Text format     Abstract available


  164. HUNG TH, Lay CJ, Tseng CW, Tsai CC, et al
    The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study.
    PLoS One. 2016;11:e0162987.
    PubMed     Text format     Abstract available


  165. SOBREVALS L, Enguita M, Quiroga J, Prieto J, et al
    Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.
    PLoS One. 2016;11:e0162955.
    PubMed     Text format     Abstract available


  166. YE Q, Qian BX, Yin WL, Wang FM, et al
    Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.
    PLoS One. 2016;11:e0163423.
    PubMed     Text format     Abstract available


  167. LIU TL, Barritt Iv AS, Weinberger M, Paul JE, et al
    Who Treats Patients with Diabetes and Compensated Cirrhosis.
    PLoS One. 2016;11:e0165574.
    PubMed     Text format     Abstract available


  168. FJELD K, Beer S, Johnstone M, Zimmer C, et al
    Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis.
    PLoS One. 2016;11:e0165567.
    PubMed     Text format     Abstract available


  169. FAN WC, Liu CW, Ou SM, Huang CC, et al
    TLR4/CD14 Variants-Related Serologic and Immunologic Dys-Regulations Predict Severe Sepsis in Febrile De-Compensated Cirrhotic Patients.
    PLoS One. 2016;11:e0166458.
    PubMed     Text format     Abstract available


  170. DELEURAN T, Vilstrup H, Overgaard S, Jepsen P, et al
    No Increased Risk for Primary Osteoarthritis in Liver Cirrhosis - A Danish Nationwide Cohort Study.
    PLoS One. 2016;11:e0167134.
    PubMed     Text format     Abstract available


  171. JEON I, Cho ES, Kim JH, Kim DJ, et al
    Feasibility of 10-Minute Delayed Hepatocyte Phase Imaging Using a 30 degrees Flip Angle in Gd-EOB-DTPA-Enhanced Liver MRI for the Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis or Cirrhosis.
    PLoS One. 2016;11:e0167701.
    PubMed     Text format     Abstract available


  172. NUNEZ-TORRES R, Macias J, Mancebo M, Frias M, et al
    The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    PLoS One. 2016;11:e0168265.
    PubMed     Text format     Abstract available


  173. TUTTOLOMONDO A, Di Raimondo D, Bellia C, Clemente G, et al
    Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
    PLoS One. 2016;11:e0165443.
    PubMed     Text format     Abstract available


  174. SARRAZIN C, Manns M, Calleja JL, Garcia-Samaniego J, et al
    HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PLoS One. 2016;11:e0168544.
    PubMed     Text format     Abstract available


  175. NOVO-VELEIRO I, Cieza-Borrella C, Pastor I, Chamorro AJ, et al
    A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.
    PLoS One. 2016;11:e0168685.
    PubMed     Text format     Abstract available


  176. GAO Y, Ren H, Meng F, Li J, et al
    Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2016;11:e0154419.
    PubMed     Text format     Abstract available


  177. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available


  178. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.
    PLoS One. 2016;11:e0164224.
    PubMed     Text format     Abstract available


  179. ZHENG S, Zhang P, Chen Y, Zheng S, et al
    Inhibition of Notch Signaling Attenuates Schistosomiasis Hepatic Fibrosis via Blocking Macrophage M2 Polarization.
    PLoS One. 2016;11:e0166808.
    PubMed     Text format     Abstract available


  180. AIKEN T, Garber A, Thomas D, Hamon N, et al
    Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
    PLoS One. 2016;11:e0166998.
    PubMed     Text format     Abstract available


  181. PUIGVEHI M, Hernandez J, Broquetas T, Coll S, et al
    Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF(R)) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    PLoS One. 2016;11:e0164883.
    PubMed     Text format     Abstract available


  182. BURKE SCHINKEL SC, Carrasco-Medina L, Cooper CL, Crawley AM, et al
    Generalized Liver- and Blood-Derived CD8+ T-Cell Impairment in Response to Cytokines in Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0157055.
    PubMed     Text format     Abstract available


  183. NGUYEN TRUONG T, Laureillard D, Lacombe K, Duong Thi H, et al
    High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
    PLoS One. 2016;11:e0153744.
    PubMed     Text format     Abstract available


  184. IBRAHIM MK, Salum GM, Bader El Din NG, Dawood RM, et al
    Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.
    PLoS One. 2016;11:e0154512.
    PubMed     Text format     Abstract available


  185. SHI L, Qin E, Zhou J, Zhao J, et al
    HIV and HCV Co-Culture Promotes Profibrogenic Gene Expression through an Epimorphin-Mediated ERK Signaling Pathway in Hepatic Stellate Cells.
    PLoS One. 2016;11:e0158386.
    PubMed     Text format     Abstract available


  186. JURADO-GARCIA J, Munoz Garcia-Borruel M, Rodriguez-Peralvarez ML, Ruiz-Cuesta P, et al
    Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.
    PLoS One. 2016;11:e0155822.
    PubMed     Text format     Abstract available


  187. AMORAS EDA S, Gomes ST, Freitas FB, Santana BB, et al
    Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection.
    PLoS One. 2016;11:e0156604.
    PubMed     Text format     Abstract available


  188. ZHANG YH, Zhao Y, Rajapaksa US, Lawrence TM, et al
    A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.
    PLoS One. 2016;11:e0158037.
    PubMed     Text format     Abstract available


  189. LIN MV, Sise ME, Pavlakis M, Amundsen BM, et al
    Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0158431.
    PubMed     Text format     Abstract available


  190. EMBADE N, Marino Z, Diercks T, Cano A, et al
    Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.
    PLoS One. 2016;11:e0155094.
    PubMed     Text format     Abstract available


  191. CHEKURI S, Nickerson J, Bichoupan K, Sefcik R, et al
    Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.
    PLoS One. 2016;11:e0159413.
    PubMed     Text format     Abstract available


  192. PELUSI S, Petta S, Rosso C, Borroni V, et al
    Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    PLoS One. 2016;11:e0163069.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: